UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, specializing in the discovery and development of therapies for severe diseases in immunology and neurology. The company’s main business activities encompass research, development, manufacturing and marketing of innovative medicines aimed at addressing high unmet medical needs. UCB focuses on advancing treatments for conditions such as epilepsy, Parkinson’s disease, atopic dermatitis and rheumatoid arthritis, leveraging both small molecules and biologics to deliver targeted therapeutic solutions.
Among UCB’s leading products are antiepileptic agents and treatments for movement disorders, supported by a robust pipeline of novel molecules and biologic candidates. The portfolio extends to immunology with therapies for chronic inflammatory diseases, including psoriasis and Crohn’s disease. UCB invests heavily in clinical research collaborations, academic partnerships and technology platforms to accelerate discovery and optimize patient outcomes, maintaining a balanced mix of on-market products and late-stage investigational compounds.
Established in 1928 as Union Chimique Belge, UCB has grown from a chemical manufacturing enterprise into a science-driven biopharma organization. Over the decades, the company expanded its footprint across Europe, North America, Latin America and the Asia-Pacific region, operating manufacturing sites, research facilities and regional offices to support global commercial operations. UCB maintains a presence in more than 40 countries, with key R&D centers in Belgium and the United States alongside strategic alliances in Asia.
Leadership at UCB is guided by a management team with deep expertise in biotechnology, clinical development and global commercial strategy. Under the direction of CEO Jean-Christophe Tellier and a seasoned executive committee, the company emphasizes patient-centric innovation, sustainability and long-term value creation. UCB continues to prioritize precision medicine approaches, digital health initiatives and environmental responsibility as part of its commitment to improving the lives of people living with severe diseases worldwide.
AI Generated. May Contain Errors.
